NY-FRAME.IO
11.2.2021 20:32:07 CET | Business Wire | Press release
Frame.io , the world’s leading cloud-based video review and approval platform, today announced Frame.io Camera to Cloud (C2C) , a secure camera-to-cloud workflow that lets customers instantly upload and stream images from on-set cameras to creative post-production teams anywhere in the world. Frame.io C2C represents the largest change in film, television, news and commercial production workflows since the advent of digital filmmaking.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210211005854/en/
Customers can view the launch event on demand at the Frame.io website and sign up for the beta today. Frame.io C2C will be available this spring to all customers at no additional cost. Download the Frame.io C2C press kit here .
Frame.io C2C provides two unique services. First, C2C enables instant proxy uploads the moment cameras stop rolling so editorial can begin within seconds of calling “cut.” In addition, Frame.io C2C can live stream footage to an authorized user’s device on or off set, allowing customers to watch production as it’s happening. This is ideal for productions working during COVID, as it greatly reduces the number of people needed on set. Frame.io C2C lets editorial and other traditionally linear parts of the creative process happen in parallel while footage is still being shot.
Getting footage from a camera into post-production is a time-consuming process that requires backing up files, transferring them to a hard drive, and shipping them to another facility. Frame.io C2C eliminates that, letting customers simultaneously view a live stream of footage as it is being shot, while automatically capturing and uploading proxies as soon as the camera stops rolling.
The camera-to-cloud workflow requires a Frame.io C2C-certified device connected to compatible cameras from Arri, RED and Sony. Once authenticated, certified devices such as the Teradek CUBE 655 and Sound Devices 888 or Scorpio recorders will record, encode, and send timecode-accurate H.264 proxy files with matching filename metadata directly to Frame.io via an encrypted and secure connection using LTE, 5G or WiFi. This allows for near real-time delivery of editable proxy files to a producer, dailies facility, or editor anywhere in the world.
“Frame.io C2C is disruptive technology that changes the traditionally linear filmmaking process, allowing both on-set production and remote post-production teams to work together at the same time,” said Michael Cioni, Global SVP of Innovation at Frame.io. “This level of collaboration brings creative teams together and allows them to work faster and more collaboratively than ever before.”
In addition, Frame.io users with proper authentication credentials can view a live stream of footage while it's being shot from the comfort of their computer, iPhone, or iPad—whether they are on set or halfway around the world. This lets collaborators instantly share ideas to help bring their creative vision to life, while everyone who needs to track production progress can stay informed.
“In today’s socially distanced world—where remote work has become the norm and the number of people on-set is limited—Frame.io C2C is a game changer,” said Emery Wells, CEO of Frame.io. “Camera to Cloud gives film, television, and commercial productions a seamless new way for creative teams to do their best work, no matter where they are.”
Frame.io C2C features best-in-class security with full TPN and SOC 2 Type 2 compliance. Created by the MPAA and CDSA, TPN is the global, industry-wide initiative that defines requirements and best practices for protecting content. Combined with rigorous access controls, Frame.io C2C is an incredibly safe way to share media with authorized viewers and collaborators.
Also introduced today, the new Frame.io Cloud Devices API and C2C certification program enables hardware and software manufacturers to create their own C2C compatible products. Frame.io C2C is launching with three groundbreaking partner integrations from Teradek, Sound Devices, and Colorfront, making it compatible with more than a dozen professional camera systems from RED, Arri, and Sony.
Manufacturers interested in building Frame.io C2C Certified software and hardware can find details at developer.frame.io .
PRICING AND AVAILABILITY
C2C features are included at no additional charge for customers with a paid Frame.io account. Flexible, new monthly enterprise plans let customers and studios purchase the service they need for the duration of their production.
Frame.io C2C is currently in beta and will ship this spring. Customers can apply to participate in the beta program at the Frame.io website. Live streaming features will be available later in 2021.
FRAME.IO C2C LAUNCH PARTNERS
Teradek designs and manufactures high-performance video solutions for broadcast and cinema. A Frame.io authenticated CUBE 655 encoder delivers live streams and camera proxy files directly into Frame.io.
Sound Devices designs and manufactures the world’s leading production sound field recorders. The latest 888 and Scorpio recorders capture and transmit original audio files directly into Frame.io.
Colorfront has developed the world’s first fully cloud dailies platform. Their Express Dailies integration with Frame.io allows labs to instantly access the video and audio assets to create dailies.
ABOUT FRAME.IO
Frame.io is the world’s leading video review and approval platform with over 1 million users. Integrated with most major professional video tools, Frame.io streamlines the creative process by centralizing assets and feedback in the cloud. This allows remote creative teams to collaborate securely and in real time from anywhere in the world.
Conceived and designed in 2015 by video creators Emery Wells and John Traver, Frame.io is intuitive and simple, yet powerful enough for creative professionals, technical administrators, and clients to use with little (or no) training. Frame.io accelerates workflows and eliminates obstacles to creativity. From script or storyboard to dailies through delivery, Frame.io has reinvented the modern video workflow.
Frame.io is backed by industry heavyweights including Insight Partners, FirstMark Capital, and Accel Partners. To learn more please visit http://frame.io .
Watch: Frame.io C2C announcement
Download: Frame.io C2C Press Kit
Watch: What is Frame.io?
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005854/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom